Ipsen S.A. operates as a biopharmaceutical company worldwide.
Reasonable growth potential second-rate dividend payer.
Share Price & News
How has Ipsen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IPN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IPN underperformed the French Pharmaceuticals industry which returned 15.5% over the past year.
Return vs Market: IPN underperformed the French Market which returned -6.6% over the past year.
Price Volatility Vs. Market
How volatile is Ipsen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most Ipsen S.A. (EPA:IPN) Stock?
3 months ago | Simply Wall StKey Things To Consider Before Buying Ipsen S.A. (EPA:IPN) For Its Dividend
4 months ago | Simply Wall StDoes Ipsen (EPA:IPN) Have A Healthy Balance Sheet?
Is Ipsen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IPN (€71.6) is trading below our estimate of fair value (€118.34)
Significantly Below Fair Value: IPN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IPN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: IPN is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IPN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IPN is overvalued based on its PB Ratio (3.4x) compared to the FR Pharmaceuticals industry average (2.5x).
How is Ipsen forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: IPN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IPN's is expected to become profitable in the next 3 years.
Revenue vs Market: IPN's revenue (1.5% per year) is forecast to grow slower than the French market (3.9% per year).
High Growth Revenue: IPN's revenue (1.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPN's Return on Equity is forecast to be high in 3 years time (20.5%)
How has Ipsen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPN is currently unprofitable.
Growing Profit Margin: IPN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IPN is unprofitable, but has reduced losses over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare IPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).
Return on Equity
High ROE: IPN has a negative Return on Equity (-3.1%), as it is currently unprofitable.
How is Ipsen's financial position?
Financial Position Analysis
Short Term Liabilities: IPN's short term assets (€1.3B) do not cover its short term liabilities (€1.5B).
Long Term Liabilities: IPN's short term assets (€1.3B) exceed its long term liabilities (€1.1B).
Debt to Equity History and Analysis
Debt Level: IPN's debt to equity ratio (74.7%) is considered high.
Reducing Debt: IPN's debt to equity ratio has increased from 2.4% to 74.7% over the past 5 years.
Debt Coverage: IPN's debt is well covered by operating cash flow (47.9%).
Interest Coverage: IPN is unprofitable, therefore interest payments are not well covered by earnings.
What is Ipsen's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IPN's dividend (1.4%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.71%).
High Dividend: IPN's dividend (1.4%) is low compared to the top 25% of dividend payers in the French market (5.03%).
Stability and Growth of Payments
Stable Dividend: IPN's dividends per share have been stable in the past 10 years.
Growing Dividend: IPN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: IPN is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: IPN's dividends in 3 years are forecast to be thoroughly covered by earnings (14.5% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Aymeric Le Chatelier (50yo)
Mr. Aymeric Le Chatelier has been an Executive Vice President and Chief Financial Officer at Ipsen S.A. since November 3, 2014 and serves as its Chief Executive Officer and served as its Interim Chief Exe ...
|CEO, CFO & Executive VP||0.42yr||no data||no data|
|Executive Vice President of Technical Operations||2.42yrs||no data||no data|
|Vice President of Investor Relations||4yrs||no data||no data|
|Executive VP & General Counsel||5.5yrs||no data||no data|
|Senior Vice-President of Global Communications||1.5yrs||no data||no data|
|Executive VP & Chief Human Resources Officer||2.25yrs||no data||no data|
|Head of New Tokyo Office||9.33yrs||no data||no data|
|Executive VP of Ethics & Social Responsibility Officer||1.42yrs||no data||no data|
|Executive VP & President of Consumer Healthcare||3.25yrs||no data||no data|
|Executive Vice President of Strategy & Transformation||3.17yrs||no data||no data|
Experienced Management: IPN's management team is considered experienced (2.8 years average tenure).
|Non-Executive Chairman||9.58yrs||€600.00k||0.17% €10.1m|
|Independent Director||3yrs||€120.00k||0.00083% €49.4k|
|Independent Director||5.08yrs||€67.36k||0.00060% €35.7k|
|Vice Chairman||12yrs||€168.85k||0.0036% €214.6k|
|Chairman of Ipsen UK||11.25yrs||no data||no data|
|Independent Director||3yrs||€135.00k||0.00060% €35.7k|
Experienced Board: IPN's board of directors are considered experienced (9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ipsen S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Ipsen S.A.
- Ticker: IPN
- Exchange: ENXTPA
- Founded: 1929
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €5.946b
- Shares outstanding: 83.04m
- Website: https://www.ipsen.com
Number of Employees
- Ipsen S.A.
- 65, quai Georges Gorse
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IPN||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Dec 2005|
|I7G||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2005|
|0MH6||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Dec 2005|
|IPSE.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2005|
|IPNP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Dec 2005|
|IPN N||BMV (Bolsa Mexicana de Valores)||Yes||Ordinary Shares||MX||MXN||Dec 2005|
|IPSE.Y||OTCPK (Pink Sheets LLC)||SPON ADR||US||USD||Aug 2007|
Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has a strategic agreement with Arix Bioscience plc; and a global licensing and joint development agreement with The University of Texas MD Anderson Cancer Center. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/03 21:28|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.